Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development
| Title | Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development |
|---|---|
| Acronym | ADAPTED |
| Website | https://www.imi-adapted.eu/ |
| Start date | 2016-10-03 |
| End date | 2020-03-31 |
| Sponsor | Innovative Medicines Initiative (IMI) |
| Institution | Fundacio ACE |
Associated cell lines
- BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32)
- BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30)
- BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27)
- BIONi010-C-6 (BIONi010-C ApoE E2/E2)
Project Description
Despite APOE being associated with risk of AD more than 20 years ago, the biological mechanisms by which APOE-ɛ4 increases the risk of developing AD is unknown. An understanding of the role of APOE-ɛ4, which is known to be the major risk factor for late onset AD, in disease pathophysiology is likely to accelerate progress in more effective treatment or prevention of the disease. ADAPTED aims to fill this gap in our knowledge by systematically exploring the APOE ε2, ε3 and ε4 allele isoforms in relevant human neurological and peripheral cell systems and organotypic 3D cultures using a range of omics tools to identify changes which can be mechanistically connected to existing hypotheses. Based on bio-informatic analyses of these results in combination with interrogation of data from existing sources ADAPTED expects to generate detailed novel hypotheses for development of more complex models of the disease and to identify new biomarkers and potential therapeutic targets and strategies. Using tissues from extreme phenotypes and homozygotes ADAPTED will identify molecular markers related to the disease mechanism and how APOE-ɛ4 interacts with other AD risk and genetic factors.